91920-58-0

Usage

Uses

Used in Pharmaceutical Industry:
cis-Tranilast is used as an antiallergic drug for the treatment of various allergic conditions, such as bronchial asthma, allergic rhinitis, and atopic dermatitis. It works by inhibiting the release of chemical mediators involved in allergic reactions, such as histamine and leukotrienes, thereby reducing inflammation and alleviating symptoms.
cis-Tranilast is used as a therapeutic agent for the management of bronchial asthma, providing relief from symptoms such as wheezing, shortness of breath, and coughing. Its antiallergic properties help in reducing airway inflammation and improving lung function.
cis-Tranilast is used as a treatment for allergic rhinitis, addressing symptoms like sneezing, itching, and a runny nose. Its ability to inhibit the release of chemical mediators involved in allergic reactions helps in providing relief from these symptoms.
cis-Tranilast is used as a medication for atopic dermatitis, a chronic skin condition characterized by itching, redness, and inflammation. Its antiallergic properties help in reducing skin inflammation and alleviating itching, improving the overall quality of life for patients with this condition.

Upstream product

• 14737-89-4 3,4-dimethoxy-trans-cinnamic acid 
• 134-20-3 2-carbomethoxyaniline 
• 70806-55-2 Tranilast 
• 53947-84-5 2-[(2-carboxyacetyl)amino]benzoic acid 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 118-92-3 anthranilic acid 

Downstream Products

• 99664-42-3 C₃₆H₃₄N₂O₁₀ 
• 70806-55-2 Tranilast 

Relevant academic research and scientific papers

Effect of UV-absorbing agents on photodegradation of tranilast in oily gels

Tranilast (TL) oily gels containing UV-absorbing agents (UV absorber) were prepared; and the effect of the agents against photodegradation of TL was investigated. When 0.1% TL oily gel without UV absorber was exposed to light, TL was photochemically decom

N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites

The transient receptor potential ankyrin 1 (TRPA1) channel is a non-selective cation channel, which detects noxious stimuli leading to pain, itch and cough. However, the mechanism(s) of channel modulation by many of the known, non-reactive modulators has not been fully elucidated. N-Cinnamoylanthranilic acid derivatives (CADs) contain structural elements from the TRPA1 modulators cinnamaldehyde and flufenamic acid, so it was hypothesized that specific modulators could be found amongst them and more could be learnt about modulation of TRPA1 with these compounds. A series of CADs was therefore screened for agonism and antagonism in HEK293 cells stably transfected with WT-human (h)TRPA1, or C621A, F909A or F944A mutant hTRPA1. Derivatives with electron-withdrawing and/or electron-donating substituents were found to possess different activities. CADs with inductive electron-withdrawing groups were agonists with desensitising effects, and CADs with electron-donating groups were either partial agonists or antagonists. Site-directed mutagenesis revealed that the CADs do not undergo conjugate addition reaction with TRPA1, and that F944 is a key residue involved in the non-covalent modulation of TRPA1 by CADs, as well as many other structurally distinct non-reactive TRPA1 ligands already reported.

Different Photodimerization Behaviour of Tranilast in α-, β- and γ-Cyclodextrin Complexes: Cavity-size and Stoichiometry Dependence

The effects of α-, β- and γ-cyclodextrins (CDxs) on the photoisomerization and photodimerization of an antiallergic drug tranilast have been kinetically investigated. α- and β-CDxs decelerate both the photoisomerization and photodimerization of 1, showing saturation kinetics, due to 1:1 complex formation.On the other hand, γ-CDx accelerates the photodimerization of 1 at higher 1:γ-CDx molar ratios, but decelerates it at lower 1:γ-CDx molar ratios.The photoisomerization of 1 is decelerated over the γ-CDxconcentration range employed.The continuous variation plot of CDx-induced circular dichroism intensities of 1 and the solubility data indicate that 1 forms inclusion complexes with γ-CDx in different stoichiometry, depending on the guest:host molar ratio.At higher 1:γ-CDx molar ratios, 1 formed the 2:1 (guest:host) complex which accelerates by about 5500 times, the dimerization of 1.With increasing γ-CDx concentration, 1:1 and 1:2 complexes are formed and the dimerization rate of 1 decreases markedly; in particular, the 1:2 complex decelerates it by 19300 times.The results reveal clear evidence for the cavity-size- and stoichiometry-dependent dimerization of 1 in CDx complexes.

Aromatic carboxylic amide derivatives

Novel aromatic carboxylic amides of the general formula: EQU1 wherein each of R1 and R2 is a hydrogen atom or an alkyl group having 1-4 carbon atoms, R3 and R4 are hydrogen atoms or together form another chemical bond, each X is a hydroxyl group, a halogen atom, an alkyl group having 1-4 carbon atoms and an alkoxy group containing 1-4 carbon atoms, and n is an integer of 1-3, with the proviso that when two Xs are alkyl or alkoxy groups, they may be connected together to form a ring, as well as pharmaceutically acceptable salts thereof. These compounds possess a strong antiallergenic action and are thus useful for treatment of asthma, hay fever, anticaria and atopic dermatitis. The above aromatic carboxylic amides can be prepared by reacting a reactive functional derivative of the general formula: EQU2 wherein R1, R2, R3, R4, X and n have the same meanings given above, with an aminobenzoic acid of the formula: And, if desired, converting the resulting amide into the corresponding salts.